{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:21:41Z","timestamp":1791177701660,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.ejca.2008.01.004","type":"journal-article","created":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T12:47:37Z","timestamp":1201956457000},"page":"528-538","source":"Crossref","is-referenced-by-count":71,"title":["Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive 9402)"],"prefix":"10.1016","volume":"44","author":[{"given":"M.","family":"Doffo\u00ebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fratt\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Grang\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Stremsdoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Blanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.X.","family":"Caroli-Bosc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Causse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Masskouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rougier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bedenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2008.01.004_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona \u2013 2000 EASL conference","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2008.01.004_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/jhep.2002.32089","article-title":"Prognostic prediction and treatment strategy in hepatocellular carcinoma","volume":"35","author":"Bruix","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","article-title":"Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma \u2013 a randomized controlled trial","volume":"94","author":"Lin","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2008.01.004_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","article-title":"A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Pelletier","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2008.01.004_bib5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","author":"Groupe d\u2019Etude et de Traitement du Carcinome H\u00e9patocellulaire","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.01.004_bib6","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial","volume":"29","author":"Pelletier","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2008.01.004_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib9","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.01.004_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camma","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2008.01.004_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.COC.0000020588.20717.BB","article-title":"Chemoembolization of hepatocellular carcinoma. Results of a metaanalysis","volume":"26","author":"Geschwind","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.004_bib13","first-page":"66","article-title":"Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma","volume":"26","author":"Elba","year":"1994","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.ejca.2008.01.004_bib14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0168-8278(05)80138-2","article-title":"Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma","volume":"20","author":"Martinez-Cerezo","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2008.01.004_bib15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.20963","article-title":"Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systemic review","volume":"103","author":"Nowak","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.01.004_bib16","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1200\/JCO.2005.05.470","article-title":"Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma","volume":"23","author":"Barbare","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.004_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2008.01.004_bib18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.01.004_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/cpt1974155443","article-title":"Minimization: a new method of assigning patients to treatment and control groups","volume":"15","author":"Taves","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2008.01.004_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","volume":"34","author":"Spitzer","year":"1981","journal-title":"J Chron Dis"},{"key":"10.1016\/j.ejca.2008.01.004_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00422215","article-title":"Critical review of the international assessments of heath-related quality of life","volume":"2","author":"Anderson","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2008.01.004_bib22","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1200\/JCO.1998.16.11.3662","article-title":"Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer","volume":"16","author":"Sloan","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.004_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jama.1994.03520080061045","article-title":"A critical appraisal of the quality of quality-of-life measurements","volume":"272","author":"Gill","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2008.01.004_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1008978512572","article-title":"Substituting proxy ratings for patient ratings in cancer clinical trials: an analysis based on a Southwest Oncology Group trial in patients with brain metastases","volume":"9","author":"Moinpour","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2008.01.004_bib25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<725::AID-SIM817>3.0.CO;2-1","article-title":"Practical approaches to minimize problems with missing quality of life data","volume":"17","author":"Simes","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2008.01.004_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<517::AID-SIM799>3.0.CO;2-S","article-title":"Missing quality of life data in cancer clinical trials: serious problems and challenges","volume":"17","author":"Bernhard","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2008.01.004_bib27","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1054\/bjoc.2001.1785","article-title":"Clinical relevance of single item quality of life indicators in cancer clinical trials","volume":"84","author":"Bernhard","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2008.01.004_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4065\/77.5.479","article-title":"Clinical Significance Consensus Meeting Group Assessing the clinical significance of single items relative to summated scores","volume":"77","author":"Sloan","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2008.01.004_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1968","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2008.01.004_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc"},{"key":"10.1016\/j.ejca.2008.01.004_bib31","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","article-title":"Tutorial in biostatistics using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2008.01.004_bib32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.20486","article-title":"Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score","volume":"40","author":"Kudo","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib33","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z","article-title":"Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients","volume":"64","author":"Nomura","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.01.004_bib34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/he.2000.5628","article-title":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma","volume":"31","author":"The Cancer of the Liver Italian Program (CLIP) Investigators","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/gut.49.2.227","article-title":"The prognostic value of quality of life scores during treatment for esophageal cancer","volume":"49","author":"Blazeby","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2008.01.004_bib36","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2014pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.004_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1026442201191","article-title":"Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy","volume":"6","author":"Dancey","year":"1997","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2008.01.004_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jama.1994.03520080061045","article-title":"A critical appraisal of the quality of quality-of-life measurements","volume":"272","author":"Feinstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2008.01.004_bib39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/bmj.322.7299.1417","article-title":"Measuring quality of life. Who should measure quality of life?","volume":"322","author":"Addington-Hall","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2008.01.004_bib40","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1200\/JCO.1997.15.3.1206","article-title":"Value of caregiver ratings in evaluating the quality of life of patients with cancer","volume":"15","author":"Sneeuw","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.004_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0895-4356(98)00040-7","article-title":"Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients","volume":"51","author":"Sneeuw","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2008.01.004_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bjc.6690655","article-title":"Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses","volume":"81","author":"Sneeuw","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2008.01.004_bib43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<781::AID-SIM821>3.0.CO;2-O","article-title":"Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials","volume":"17","author":"Fairclough","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2008.01.004_bib44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0399-8320(05)82175-X","article-title":"Longitudinal quality of life study in patients with metastatic gastric cancer Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology","volume":"29","author":"Bonnetain","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.ejca.2008.01.004_bib45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American Cohort","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2008.01.004_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.ejca.2008.01.004_bib47","doi-asserted-by":"crossref","unstructured":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751\u20135.","DOI":"10.1002\/hep.510280322"},{"key":"10.1016\/j.ejca.2008.01.004_bib48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire","volume":"31","author":"Chevret","year":"1999","journal-title":"J Hepatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T17:17:51Z","timestamp":1737911871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804908000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0959804908000087"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2008.01.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}